PapersFlow Research Brief
Psoriasis: Treatment and Pathogenesis
Research Guide
What is Psoriasis: Treatment and Pathogenesis?
Psoriasis: Treatment and Pathogenesis refers to the study of immune mechanisms driving psoriasis, centered on the differentiation of pathogenic TH17 cells that produce IL-17 under the influence of IL-23 and TGF-β, alongside strategies to measure disease impact and classify related psoriatic arthritis.
The field encompasses 69,082 papers on reciprocal pathways generating pathogenic effector TH17 cells and regulatory T cells in autoimmune inflammation like psoriasis, involving cytokines such as IL-23, IL-17, and TGF-β. Key works establish TH17 cells as a distinct lineage from TH1 and TH2, driven by IL-23 to induce inflammation. Tools like the Dermatology Life Quality Index (DLQI) provide practical measurement of psoriasis impact on patients.
Topic Hierarchy
Research Sub-Topics
TH17 Cell Differentiation
TH17 cell differentiation studies transcriptional regulation, cytokine signaling pathways (TGF-β, IL-6, IL-23), and epigenetic control of RORγt expression. Researchers identify lineage commitment factors and plasticity with other T cell subsets.
IL-23/IL-17 Axis in Psoriasis
IL-23/IL-17 axis in psoriasis investigates dendritic cell IL-23 production, TH17/TC17 effector function, and keratinocyte responses driving lesional inflammation. Researchers study blockade efficacy and relapse mechanisms.
Pathogenic vs Regulatory TH17 Cells
Pathogenic versus regulatory TH17 cells compares GM-CSF+IFNγ+ pathogenic effectors with IL-10+ anti-inflammatory subsets in autoimmune contexts. Researchers profile transcriptomic differences and conversion plasticity.
IL-17 Producing T Cell Plasticity
IL-17 producing T cell plasticity examines transdifferentiation between TH17, TR1, TFH, and cytotoxic lineages under inflammatory cues. Researchers track epigenetic modifications and environmental drivers of subset switching.
Cytokine Regulation of TH17 Responses
Cytokine regulation of TH17 responses dissects IL-1β, IL-21, and aryl hydrocarbon receptor signaling in pathogenic effector generation. Researchers develop mouse models and single-cell profiling of cytokine-responsive states.
Why It Matters
Understanding TH17 cell differentiation enables targeted therapies blocking IL-17 or IL-23 pathways in psoriasis treatment. Finlay and Khan (1994) introduced the Dermatology Life Quality Index (DLQI), applied in routine clinical use across 120 patients with skin diseases to quantify treatment effects on quality of life, now standard in dermatology trials. Classification criteria for psoriatic arthritis by Taylor et al. (2006), developed from a large international study comparing PsA clinic attendees with other arthropathies, improve diagnostic accuracy for comorbid conditions affecting over 30% of psoriasis patients.
Reading Guide
Where to Start
"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells" by Bettelli et al. (2006), as it provides the foundational framework linking TH17/Treg balance to psoriasis pathogenesis, cited 6831 times.
Key Papers Explained
Bettelli et al. (2006) establish reciprocal TH17/regulatory T cell pathways; Ivanov et al. (2006) identify RORγt directing IL-17+ differentiation; Harrington et al. (2005) confirm distinct TH17 lineage from TH1/TH2; Korn et al. (2009) review IL-17/Th17 biology; Langrish et al. (2005) show IL-23 driving pathogenic populations—building from lineage discovery to cytokine mechanisms.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Field centers on TH17/IL-23 pathways with no recent preprints or news; Ivanov et al. (2006) and Veldhoen et al. (2006) highlight ongoing RORγt and TGF-β roles in unresolved human-psoriasis translation.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Reciprocal developmental pathways for the generation of pathog... | 2006 | Nature | 6.8K | ✕ |
| 2 | Dermatology Life Quality Index (DLQI)-a simple practical measu... | 1994 | Clinical and Experimen... | 5.3K | ✕ |
| 3 | The Orphan Nuclear Receptor RORγt Directs the Differentiation ... | 2006 | Cell | 5.0K | ✓ |
| 4 | IL-17 and Th17 Cells | 2009 | Annual Review of Immun... | 4.7K | ✕ |
| 5 | Interleukin 17–producing CD4+ effector T cells develop via a l... | 2005 | Nature Immunology | 4.6K | ✕ |
| 6 | A distinct lineage of CD4 T cells regulates tissue inflammatio... | 2005 | Nature Immunology | 4.2K | ✓ |
| 7 | IL-23 drives a pathogenic T cell population that induces autoi... | 2005 | The Journal of Experim... | 4.0K | ✓ |
| 8 | Classification criteria for psoriatic arthritis: Development o... | 2006 | Arthritis & Rheumatism | 3.6K | ✕ |
| 9 | Measurement of Cutaneous Inflammation: Estimation of Neutrophi... | 1982 | Journal of Investigati... | 3.6K | ✓ |
| 10 | TGFβ in the Context of an Inflammatory Cytokine Milieu Support... | 2006 | Immunity | 3.5K | ✓ |
Frequently Asked Questions
What role do TH17 cells play in psoriasis pathogenesis?
TH17 cells produce IL-17 and drive autoimmune inflammation in psoriasis through pathways distinct from TH1 and TH2 lineages. Korn et al. (2009) describe CD4+ T cells differentiating into IL-17-producing effectors under IL-23 influence. IL-23 drives pathogenic T cell populations inducing tissue inflammation, as shown by Langrish et al. (2005).
How does IL-23 contribute to psoriasis?
IL-23 promotes differentiation of proinflammatory IL-17+ T helper cells essential for psoriasis-like inflammation. Langrish et al. (2005) demonstrated IL-23 drives pathogenic T cells unlike IL-12's Th1 promotion. This heterodimeric cytokine with p19 and p40 subunits sustains effector functions in autoimmune settings.
What is the Dermatology Life Quality Index in psoriasis treatment?
The Dermatology Life Quality Index (DLQI) is a simple questionnaire assessing disease and treatment impact on patient lives. Finlay and Khan (1994) validated it in 120 patients with various skin diseases including psoriasis. It enables routine clinical measurement of cutaneous inflammation effects.
How are TH17 cells generated in inflammatory contexts?
TGF-β with inflammatory cytokines like IL-23 supports de novo IL-17-producing T cell differentiation. Veldhoen et al. (2006) showed this in inflammatory milieus overriding regulatory T cell pathways. Bettelli et al. (2006) outlined reciprocal developmental pathways balancing pathogenic TH17 and regulatory T cells.
What defines classification criteria for psoriatic arthritis?
Taylor et al. (2006) developed new criteria from prospective data on PsA clinic attendees versus other arthropathies. These outperform prior standards for diagnosing psoriasis-associated arthritis. The study involved consecutive patients to construct data-driven classification.
Open Research Questions
- ? How do microenvironmental cues precisely balance TH17 pathogenic effector differentiation versus regulatory T cell generation in psoriasis lesions?
- ? What upstream regulators beyond RORγt direct IL-17 cytokine profiles in human versus mouse TH17 cells?
- ? Can IL-23 blockade fully resolve tissue inflammation or does residual TH17 pathogenicity persist?
- ? How does TGF-β dosage with IL-23 quantitatively shift TH17 versus Treg outcomes in psoriatic skin?
- ? What neutrophil infiltration markers best correlate with TH17-driven psoriasis severity?
Recent Trends
The cluster holds 69,082 works with no specified 5-year growth rate; highly cited papers from 2005-2009 dominate TH17/IL-23 discoveries, but no recent preprints or news indicate steady focus on established cytokine pathways without new surges.
Research Psoriasis: Treatment and Pathogenesis with AI
PapersFlow provides specialized AI tools for Immunology and Microbiology researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Psoriasis: Treatment and Pathogenesis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Immunology and Microbiology researchers